Image source

This article updates the stock performances of the 13 companies with the largest market capitalizations which are tracked in the munKNEE Pure-Play Marijuana and Psychedelic Compounds-Based Drug Stocks Index.

The constituents in both our Pure-Play Marijuana Drug Stocks Index and our Pure-Play Psychedelic Compounds-Based Drug Stocks Index have hyperlinks to 3 areas of additional information that are imperative for any individual considering investing in this sector to open and read carefully, namely:

1. The company name is hyperlinked to its website to provide you with a description of the company and an analysis of its stock.
2. The trading symbol is hyperlinked to additional financial data and commentary on the company (where available).
3. The percentage increase YTD is hyperlinked to a chart of the company's stock performance YTD.

The munKNEE Pure-Play Marijuana Drug Stocks Index

This Index consists of the 4 marijuana drug stocks with market capitalization of at least $40M and trade for at least $0.20/share. The Index was DOWN -11.9% this past week on top of a -5.7% decline the previous week and is now down, -26.5% YTD and  -74.2% from its peak in 2021. Their performances last week are presented below in descending order:

1. Corbus Pharmaceuticals (CRBP): DOWN -2.9% last week; (DOWN -45.2% YTD)
2. Allied Corp. (ALID): DOWN -5.7%; (DOWN -6.8% YTD)
3. Revive Therapeutics (RVVTF): DOWN -14.3%; (DOWN -33.3% YTD)
4. Zynerba Pharmaceuticals (ZYNE): DOWN -17.7%; (DOWN -34.0% YTD)

The munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index

This Index consists of 9 psychedelic compound-based drug stocks which are divided into 2 groups based on their market capitalizations: $40M>$399.9M (Group 1) and $400M+ (Group 2).

Group 1

There are 5 constituents in Group 1 and they were DOWN -9.1%, on average, last week and are now DOWN -36.1% YTD and DOWN -80.2% from their average peaks in 2021. Their performances are presented below in descending order:

1. Small Pharma (DMTTF): No Change in price last week; (DOWN -8.0% YTD)
2. Numinus (NUMIF): No Change; (DOWN -4.8% YTD)
3. Cybin (CYBN): DOWN -1.1%; (DOWN -25.0% YTD)
4. Seelos (SEEL): DOWN -8.5%; (DOWN -40.5% YTD)
5. Field Trip (FTRP): DOWN -17.6%; (DOWN -46.7% YTD)

Group 2

The 4 constituents in Group 2 went DOWN -6.0%, on average, last week, and are now DOWN -36.9%, on average, YTD, and DOWN -70.8% from their average peaks in 2021. Their performances are presented below in descending order:

1. GH Resources (GHRS): DOWN -2.3% last week; (DOWN -32.4% YTD)
2. Atai (ATAI): DOWN -7.4%; (DOWN -32.9% YTD)
3. Compass Pathways (CMPS): DOWN -9.1%; (DOWN -43.8% YTD)
4. Mind Medicine (MNMD): DOWN -14.8; (DOWN -24.6% YTD)

In summary, the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index went DOWN -6.4% last week on top of a -4.7% decline the week before and is now DOWN -36.8% YTD and DOWN -72.1% from its peak in 2021.